Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells

New findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, ...

Merck: Initiating "Strong Buy" On Shift To Qlex SC Injection For Solid Tumors

Despite flat overall Q2 2025 sales, Keytruda's continued strong performance in oncology supports long-term bullish prospects ...
WPRI 12

Data presented at AACR IO meeting in Los Angeles

CAMBRIDGE, United Kingdom, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic ...
pharmaphorum

Verona shareholders back $10bn MSD takeover

Investors in Verona – a specialist in respiratory medicines – overwhelmingly gave their blessing to MSD's $107-per-share ...
Pharmabiz

Kazia Therapeutics inks collaboration and in-licensing agreement with QIMR Berghofer for PD-L1 protein degrader programme

Kazia Therapeutics inks collaboration and in-licensing agreement with QIMR Berghofer for PD-L1 protein degrader programme: Sydney, Australia Friday, October 10, 2025, 16:00 Hrs [I ...
KRQE Blogs

Data presented at AACR Annual Meeting in Chicago

CAMBRIDGE, United Kingdom, April 29, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic ...